ReviewCurrent treatment options in oncology2016
Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
Review in Current treatment options in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.JCO oncology practice · 2023Trial
- Trends in the Utilization ofCurrent oncology (Toronto, Ont.) · 2025Article
- Exploring the Role of Communication Asset Mapping (CAM) as a Strategy to Promote Hereditary Cancer Risk Assessment Information Within African American Communities.International journal of environmental research and public health · 2025Article
- Predicting Survival Outcomes for Patients with Ovarian Cancer Using National Cancer Registry Data from Taiwan: A Retrospective Cohort Study.Women's health reports (New Rochelle, N.Y.) · 2025Article
- Genetic Testing Uptake among Ovarian Cancer Survivors in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study.Cancers · 2024Article
- Predicting breast cancer risk in a racially diverse, community-based sample of potentially high-risk women.Cancer medicine · 2022Article
- Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman StudyCurrent oncology (Toronto, Ont.) · 2022Article
- Development and pilot testing of a training for bilingual community education professionals about hereditary breast and ovarian cancer among Latinas: ÁRBOLES Familiares.Translational behavioral medicine · 2022Article
- Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.JAMA network open · 2020Article
- Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.Current breast cancer reports · 2020Article
- Strategies to enhance identification of hereditary breast cancer gene carriers.Expert review of molecular diagnostics · 2020Article
- Improving access to cancer genetic services: perspectives of high-risk clients in a community-based setting.Journal of community genetics · 2020Article
- Racial/Ethnic Disparities in BRCA Counseling and Testing: a Narrative Review.Journal of racial and ethnic health disparities · 2019Review
- A family pedigree of malignancies associated withHereditary cancer in clinical practice · 2019Article
- A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of different racial and ethnic backgrounds.Journal of cancer metastasis and treatment · 2019Article
- Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes.Cancer causes & control : CCC · 2018Article
- Racial health disparities in ovarian cancer: not just black and white.Journal of ovarian research · 2017Review
- Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
- Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study.Cancer medicine · 2017Article
- Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries.Hereditary cancer in clinical practice · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementOvarian cancer is an uncommon but deadly disease. There is no effective screening for the disease, and the majority of women with ovarian cancer present in advanced stage and eventually die from their disease. The majority of families with multiple cases of breast and ovarian cancer are found to carry germline mutations in BRCA1/2. Recent, more sensitive sequencing techniques have shown that nearly 20 % of ovarian cancer is associated with germline mutations in cancer susceptibility genes, with approximately 15 % accounted for by deleterious mutations in BRCA1/2. Women found to have mutations in BRCA1/2 can be empowered to make decisions on reproduction, cancer prevention, or treatment that may either avoid cancer or prolong survival. Though initial studies suggested that African American (AA) women were significantly less likely than White women to have mutations in BRCA1/2, this has been found to be untrue. Despite this revelation, and the clear importance of BRCA1/2 mutation status to appropriate clinical management, AA women still undergo genetic counseling and testing at much lower rates than do comparable White women. This disparity is not explained by factors such as calculated risk of a mutation, insurance coverage, or previous knowledge of the availability of testing. To date, no effective strategies have been identified that can overcome this disparity. Possible approaches include use of patient navigators, online social media, or EMR-based decision support aids. Funders should support research in this area, as it represents an actionable means to decrease the burden of ovarian and breast cancer in AA women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.